Antidepressant medication dispensing among montelukast initiators

Journal of Asthma

Volumn 50, Issue 9, 2013, Pages 990-995

  Zhou, Esther H ^a   Kaplan, Sigal ^a   Mosholder, Andrew ^a   Moeny, David ^a   Ding, Yulan ^a   Wu, Yute ^a   Iyasu, Solomon ^a   Hammad, Tarek A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Antidepressant; Interrupted time series analysis; Montelukast

Indexed keywords

ANTIDEPRESSANT AGENT; CORTICOSTEROID; FLUTICASONE; MONTELUKAST; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; ADVERSE OUTCOME; ARTICLE; ASTHMA; CHILD; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PRESCHOOL CHILD; PRESCRIPTION; SCHOOL CHILD; TIME SERIES ANALYSIS;

ACETATES; ADOLESCENT; ANTI-ASTHMATIC AGENTS; ANTIDEPRESSIVE AGENTS; ASTHMA; DEPRESSION; FEMALE; HUMANS; MALE; QUINOLINES; YOUNG ADULT;

EID: 84885928570     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2013.823445     Document Type: Article

References (23)

1. Singulair. Highlights of prescribing information. Initial US approval: 1998. Available from: Http://www.accessdata.fda.gov/ drugsatfda-docs/label/2010/ 020829s052lbl.pdf [last accessed 17 Sep 2012
2. US Food and Drug Administration. Early Communication about an ongoing safety review of montelukast (Singulair). 2008. Available from: Http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafe tyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm070618.htm [last accessed 27 Feb 2013
3. US Food and Drug Administration. Follow-up to the March 27, 2008 communication about the ongoing safety review of montelukast (Singulair). 2009. Available from: Http://www.fda.gov/ Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatients andProviders/ DrugSafetyInformationforHeathcareProfessionals/ ucm079523.htm [last accessed 27 Feb 2013
4. US Food and Drug Administration. Updated information on leukotriene inhibitors: Montelukast (marketed as Singulair), zafirlukast (marketed as Accolate), and zileuton (marketed as Zyflo and Zyflo CR). 2009. Available from: Http://www.fda.gov/ Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatients andProviders/DrugSafetyInformationforHeathcareProfessionals/ ucm165489.htm [last accessed 27 Feb 2013
5. FDA. Updated information on leukotriene inhibitors: Montelukast (marketed as Singulair), Zafirlukast (marketed as Accolate), and Zileuton (marketed as Zyflo and Zyflo CR). 2009. Available from: Http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInfor mationforPatientsandProviders/ DrugSafetyInformationforHeath careProfessionals/ucm165489.htm [last accessed 27 Feb 2013
6. Manalai P, Woo J, Postolache TT. Suicidality and montelukast. Expert Opin Drug Saf 2009;8:273-282
7. Wallerstedt SM, Brunlof G, Sundstrom A, Eriksson AL. Montelukast and psychiatric disorders in children. Pharmacoepidemiol Drug Saf 2009;18:858-864
8. Schumock GT, Stayner LT, Valuck RJ, Joo MJ, Gibbons RD, Lee TA. Risk of suicide attempt in asthmatic children and young adults prescribed leukotriene-modifying agents: A nested case-control study. J Allergy Clin Immunol 2012;130: 368-375
9. Philip G, Hustad C, Noonan G, Malice MP, Ezekowitz A, Reiss TF, Knorr B. Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol 2009;124:691-696
10. Philip G, Hustad C, Noonan G, Malice MP, Noonan G, Ezekowitz A, Reiss TF, Knorr B. Analysis of behavior-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol 2009;124:699-706
11. Staffa JA, Dal Pan GJ. Regulatory innovation in postmarketing risk assessment and management. Clin Pharmacol Ther 2012;91: 555-557
12. Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 2009;169:1756-1761
13. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002;27:299-309
14. Kaplan S, Zhou EH, Iyasu S. Characterization of long-Acting beta(2)-Adrenergic agonists utilization in asthma patients. J Asthma 2012;49:1079-1085
15. Oraka E, King ME, Callahan DB. Asthma and serious psychological distress prevalence and risk factors among US adults, 2001-2007. Chest 2010;137:609-616
16. Hurwitz EL, Morgenstern H. Cross-sectional associations of asthma, hay fever, and other allergies with major depression and low-back pain among adults aged 20-39 years in the United States. Am J Epidemiol 1999;150:1107-1116
17. Kewalramani A, Bollinger ME, Postolache TT. Asthma and mood disorders. Int J Child Health Hum Dev 2008;1:115-123
18. Kuo CJ, Chen VC, Lee WC, Chen WJ, Ferri CP, Stewart R, Lai TJ, et al. Asthma and suicide mortality in young people: A 12-year follow-up study. Am J Psychiatry 2010;167:1092-1099
19. Brookhart MA, Sturmer T, Glynn RJ, Rassen J, Schneeweiss S. Confounding control in healthcare database research: Challenges and potential approaches. Med Care 2010;48:S114-S120
20. Hammad TA, Pinheiro SP, Neyarapally GA. Secondary use of randomized controlled trials to evaluate drug safety: A review of methodological considerations. Clin Trials 2011;8: 559-570
21. Garbe E, Suissa S. Hormone replacement therapy and acute coronary outcomes: Methodological issues between randomized and observational studies. Hum Reprod 2004;19:8-13
22. Kaufman DW. Interpretation of associations in pharmacoepidemiology. Semin Hematol 2008;45:181-188
23. Kung H-C, Hoyert DL, Xu J, Murphy SL; Division of Vital Statistics. National Vital Statistics Reports. Death: Final data for 2005. Available from: Http://www.cdc.gov/nchs/data/nvsr/nvsr56/ nvsr56-10.pdf [last accessed 17 Sep 2012